Steven Robert Pacelli

Steven Robert Pacelli (chief executive) discloses dealings in Dexcom Inc to SEC (Form 4). We count 340 filings; the first trade dates from 19 November 2008 and the latest from 24 November 2023.

In open-market terms, that means 1 purchase worth €7,997 on one side and 234 sales worth €69.2M on the other. On balance, insiders were net sellers of €69.2M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 14 share grants and 52 option exercises. Since January 2023: no purchases and 13 sales on the market.

Most recently, on 27 November 2023, the filings show an open-market sale worth €42k in Dexcom Inc. The last insider purchase was made public on 20 November 2008, 6,562 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.